RECENT NEWS

Roche has opened its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the new centre brings together teams of scientists and researchers to accelerate scientific discoveries for patients.

Following the publication of Lord Darzi’s report into the NHS, the Institute of Biomedical Science (IBMS) and British In Vitro Diagnostics Association (BIVDA) have issued responses.

The Prime Minister Sir Keir Starmer is pledging the ‘biggest reimagining of our NHS since its birth’, following the publication of Lord Darzi’s full and independent investigation into the state of the NHS.

The September issue of PiP has now been published and is available to read online.

Registration is still open for The Power to Disrupt - Clinical Diagnostics Expo UK, the ninth face-to-face event provided by Thornhill Healthcare Events in partnership with POCTInnovators.com. Taking place in London on Monday 16 September, Pathology in Practice will be supporting the event with a special supplement.

A new, rapid blood test that spots whether people are having a heart attack could improve the treatment of people presenting with chest pain at emergency departments, according to late breaking research presented in a Hot Line Session at this year’s ESC Congress 2024 in London.

Sophia Genetics has announced a new partnership agreement with AstraZeneca, which will accelerate the deployment of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months.

A scientific team supported by the National Institutes of Health (NIH) has created a preclinical blood test to identify adults most likely to develop severe respiratory conditions, including chronic obstructive pulmonary disease (COPD).

Fimlab Laboratories, Finland’s largest provider of laboratory services, research, and training, is taking the next step on its digital pathology journey with Proscia, a global leader in AI-enabled pathology solutions for precision medicine. The company will use Proscia’s software platform to help its pathologists generate more precise results with artificial intelligence (AI).

A Menarini Diagnostics and Nucleix have announced a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck test in Europe. Under the new agreement, Menarini will assume exclusive marketing of the non-invasive Bladder EpiCheck test in Europe in the months ahead, aiming to accelerate its adoption.

The FDA has granted approval on Illumina's TruSight Oncology Comprehensive assay, marking a transformative milestone in cancer diagnostics. This innovative in vitro diagnostic (IVD) kit is the first of its kind, offering distributable comprehensive genomic profiling (CGP) with pan-cancer companion diagnostic claims.

Roche has announced the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology.

AI technology firm Paige has unveiled Alba, a clinical-grade multimodal co-pilot designed to revolutionise personalised medicine and precision oncology. Using the power of Paige’s Foundation Models, Alba delivers AI-driven patient insights in real-time and marks a significant step toward Artificial General Intelligence (AGI).

Proscia and Smart Reporting, a provider of medical documentation software, have partnered to help pathologists inform treatment decisions. The companies will deliver a unified experience around a product integration that enables pathologists to efficiently make and comprehensively report on precise diagnoses, all within a single user interface.

Artificial intelligence (AI)-powered cancer diagnostics firm Ibex Medical Analytics has unveiled the latest advancements in its innovative product platform, with an expanded focus on breast cancer.

Seegene and Springer Nature have joined forces to launch 'Nature Awards MDx Impact Grants in partnership with Seegene', a new project for the development of diagnostic assays. The program empowers researchers worldwide to develop innovative diagnostic assays using Seegene's advanced multiplex PCR technology.

Research supported by the National Institutes of Health has found that measuring two types of fat in the bloodstream along with C-reactive protein (CRP), a marker of inflammation, can predict a woman’s risk for cardiovascular disease decades later.

AMLo Biosciences has announced the successful receipt of the UKCA mark for AMBLor, a groundbreaking histopathological biomarker test for the personal identification of early-stage melanomas at low risk of progression, post staging diagnosis.

In response to disparities in cervical cancer screening, IBMS and BD unveil a report advocating for self-sampling and innovative technologies to ensure equitable access and improve health outcomes.

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine that primes the immune system to recognise and fight cancer cells.